Pure Global
NCT06253429

Alpha-lipoic Acid in Diabetic Nephropathy

Oxidative Stress in Children and Adolescents With Diabetic Nephropathy and the Role of Adjuvant Alpha-lipoic Acid as an Antioxidant
Ain Shams University·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes
Drug/Device/Intervention
Thioctic Acid 333 MG Oral Capsule
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Jan 01, 2023
End date
Feb 01, 2024
Enrollment
30 participants
Primary outcome

Changes in Total antioxidant capacity and Malondialdehyde,Changes in urinary albumin excretion rate

Summary

Endothelial dysfunction in diabetes is a central event in the pathogenesis of different
 microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe
 microvascular complication.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06253429
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06253429 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.